What science
can do
Annual Report & Form 20-F
Information 2017
can do
Information 2017
One of the Board’s basic responsibilities is to set our strategy and monitor progress towards meeting our objectives, so that we bring our science to patients, create value for society, and reward you, our shareholders.
2017 represented a defining year for AstraZeneca. 2018 will be equally important as we seek to deliver the full potential of our medicines and ensure we deliver our science to patients around the world.
In 2017, our financial performance reflected the launch of several new medicines, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR in the US.
Key Highlights
Total Revenue
$22.5bn
Net cash flow from operating activities
$3.6bn
Reported operating profit
$3.7bn
Core operating profit
$6.9bn
Reported EPS
$2.37
Core EPS
$4.28
At a Glance
We are a global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.
Product Sales
$20,152m
2016: $21,319m
2015: $23,641m
By therapeutic area
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Portfolio_of_specialty_and_primary_care_products_(product_sales)-01.png)
By geography
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Global_commercial_presence_with_strength_in_Emerging_Markets_(product_sales)-01.png)
61,100
100%
84%
Dividend per Ordinary Share
for 2017
1st interim dividend
$0.90
Pence: 68.9
SEK: 7.40
Payment date: 11 September 2017
2nd interim dividend
$1.90
Pence: 133.6
SEK: 14.97
Payment date: 19 March 2018
Total
$2.80
Pence: 202.5
SEK: 22.37
Strategy
We announced our strategy for returning to growth in 2013. We moved on from the first phase in our journey, focused on rebuilding our pipeline, in 2015. The second stage is crucial as we drive our Growth Platforms forward, continue to launch new medicines and make them available to patients. As we look ahead to 2020 and beyond, continued investment in our pipeline will keep us on track to return to sustainable growth in line with our targets.
In 2017, our strategic priorities were focused under the three pillars described below.
-
Achieve Scientific Leadership
We are focusing our science on three therapy areas and accelerating our pipeline. We are also transforming our way of working.
-
Return to Growth
We are focusing on our Growth Platforms and transforming the business through specialty care, devices and biologic medicines. Targeted business development reinforces our efforts.
-
Be a Great Place to Work
We are evolving our culture and simplifying our business. We want to attract and retain the best talent. We also want to do business sustainably.
Therapy Area Highlights
We have transformed our drugs portfolio by focusing on three therapy areas: Oncology, Cardiovascular & Metabolic Diseases (CVMD) and Respiratory, while being selectively active in Other Disease Areas.
Oncology
$4,024m
Product Sales (2016: $3,383m, 2015: $2,825m)
Highlights
- Tagrisso sales up 126% (126% at CER) and approved in more than 60 markets
- Iressa sales of $528 million, up 3% (3% at CER); Lynparza sales of $297 million, up 36% (35% at CER)
- Imfinzi launched in the US in May and sales of $19 million; Calquence launched in the US in October and sales of $3 million
Cardiovascular & Metabolic Diseases
$7,266m
Product Sales (2016: $8,116m, 2015: $9,489m)
Highlights
- Brilinta sales of $1,079 million, up 29% (29% at CER) and Forxiga sales of $1,074 million, up 29% (28% at CER)
- Sales of Onglyza were down by 15% (16% at CER) to $611 million
- Legacy sales: Crestor down 30% (30% at CER) to $2,365 million
Respiratory
$4,706m
Product Sales (2016: $4,753m, 2015: $4,987m)
Highlights
- Symbicort sales of $2,803 million, down 6% (6% at CER)
- Sales of Pulmicort up 11% (12% at CER) at $1,176 million
- Fasenra approved in the US in November
Other Disease Areas
$4,156m
Product Sales (2016: $5,067m, 2015: $6,340m)
Highlights
- Nexium sales down 4% (3% at CER) to $1,952 million
- Sales of Synagis up 1% (1% at CER) to $687 million
- Seroquel XR sales of $332 million, down 55% (55% at CER)
- FluMist/Fluenz sales of $78 million, down 25% (28% at CER)
